Complete index

Every compound we track, A–Z

The full alphabetical directory of every peptide and related substance in the atlas, with its current U.S. regulatory status. Organized by name here; the atlas groups the same facts by status, and By jurisdiction cuts them by regulator.

19 compounds tracked · updated ET

  • In limbo14
  • Restricted4
  • Compounding-legal1
  1. BPC-157Body Protection Compound 157, BepecinIn limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
  2. CagrilintideAM833, long-acting amylin analogRestrictedInvestigational only - no approved form exists anywhere; cannot be compounded; the CagriSema combination is under FDA reviewNext: Dec 31, 2026 · in 78 days
  3. CJC-1295Modified GRF 1-29, DAC:GRFIn limboPCAC voted against listing (Dec 2024); off Category 2, not on the 503A list
  4. Emideltide (DSIP)Delta sleep-inducing peptide, DSIPIn limboPCAC voted against listing (6-7, Jul 24, 2026); not on the 503A list
  5. EpitalonEpithalon, EpithaloneIn limboPCAC recommended listing (reported 7-4, Jul 24, 2026) - advisory only; still not on the 503A list
  6. GHK-CuCopper tripeptide-1, Copper peptideIn limboInjectable removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027Next: Feb 28, 2027 · in 137 days
  7. IpamorelinIpamorelin acetateIn limboPCAC voted against listing (Oct 2024); off Category 2, not on the 503A list
  8. KPVLysine-proline-valine, Lys-Pro-ValIn limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
  9. Melanotan IIMT-II, MT-2In limboOff Category 2, not on the 503A list; PCAC review expected before end of Feb 2027Next: Feb 28, 2027 · in 137 days
  10. MOTS-cMOTs-C, Mitochondrial-derived peptideIn limboPCAC recommended listing (7-5, Jul 23, 2026) - advisory only; still not on the 503A list
  11. NAD+Nicotinamide adenine dinucleotide, NADIn limboNot on the finalized 503A list; no federal ban; compounded in a gray area
  12. RetatrutideLY3437943, GIP/GLP-1/glucagon triple agonistRestrictedInvestigational only - no approved form exists anywhere; cannot be compounded; FDA warning letters target sellersNext: Mar 31, 2027 · in 168 days
  13. SelankSelank acetate, TP-7In limboRemoved from Category 2 (2024); not on the 503A list; no scheduled review
  14. Semaglutide (compounded)Ozempic, WegovyRestrictedEnforcement discretion ended; routine compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending
  15. SemaxSemax acetateIn limboPCAC recommended listing (8-5, Jul 24, 2026) - advisory only; still not on the 503A list
  16. SermorelinGRF 1-29, GerefCompounding-legalCategory 1 of the interim 503A list - compoundable with a prescription
  17. TB-500 (Thymosin Beta-4)TB-500, Thymosin Beta-4In limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
  18. Thymosin Alpha-1Thymalfasin, ZadaxinIn limboOff Category 2, never in Category 1; PCAC declined Dec 2024
  19. Tirzepatide (compounded)Mounjaro, ZepboundRestrictedEnforcement discretion ended; broad compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending

What the statuses mean

Under review
Actively before the FDA advisory committee; a decision is pending and the status can move.
In limbo
Moved on paper - nominated, removed from a restricted list, or recommended by an FDA committee - but not added to the 503A list. The headline implies a change; the legal status has not moved.
Restricted
Prescription-only, banned, controlled, or under active FDA enforcement.
Compounding-legal
On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.
Unscheduled
No specific federal action; unaddressed at this time.

Status is never reduced to “legal / illegal.” Each badge pairs a color with a word, and every entry links to the primary source behind it. How we track it.